tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Medicinova (MNOV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRNResearch Report) and Medicinova (MNOVResearch Report).

BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical received a Hold rating and a $70.00 price target from Wedbush analyst Andreas Argyrides today. The company’s shares closed last Friday at $75.08, close to its 52-week low of $71.59.

According to TipRanks.com, Argyrides has 0 stars on 0-5 stars ranking scale with an average return of -35.1% and a 5.0% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and Kala Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin Pharmaceutical with a $108.21 average price target.

See the top stocks recommended by analysts >>

Medicinova (MNOV)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Medicinova, with a price target of $6.00. The company’s shares closed last Friday at $2.49, close to its 52-week low of $2.09.

According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -31.4% and a 20.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medicinova with a $6.00 average price target, a 135.3% upside from current levels. In a report issued on June 8, Maxim Group also assigned a Buy rating to the stock with a $6.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed